HBM1022 / Harbour BioMed - LARVOL DELTA

Harbor BioMed-B (02142): Start of HBM1022 clinical trial and obtain new drug research approval from US Food and Drug Administration [Google translation] (Zhitong Finance) - "Harbor Biomedical-B (02142) announced that the company has obtained the New Drug Application (IND) from the US Food and Drug Administration (FDA) to initiate clinical trials of the monoclonal antibody HBM1022 in the United States....With its uniqueness, HBM1022 is expected to show therapeutic potential in a variety of solid tumors enriched in CCR8-positive regulatory T cells, including breast cancer, colon cancer, gastric cancer, non-small cell lung cancer, head and neck cancer, etc."

IND • Breast Cancer • Colon Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

HBM1022: an afucosylated anti-CCR8 antibody, depletes specifically tumor infiltrating Tregs and inhibits tumor growth with excellent safety profile in preclinical studies (SITC 2022) - "HBM1022 exhibits a potent antitumor activity as monotherapy and in combination with anti-PD (L)1 antibodies. HBM1022 has favorable pharmacokinetic properties and an excellent safety profile in cynomolgus monkey, which suggests a potential good safety profile in human."

IO biomarker • Preclinical • Bladder Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • CCR8

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting (PRNewswire) - "Harbour BioMed...announced today that the Company will present new preclinical data of five portfolio assets including HBM7008, HBM7004, HBM1047, HBM1020 and HBM1022 in five poster presentations at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, via in person/virtual attendance, November 8-12, 2022."

Preclinical • Oncology • Solid Tumor

Harbour BioMed Announces 2022 Interim Results (PRNewswire) - "HBM9027 is currently in preclinical studies and is expected to be submitted for an IND application in 2023. A number of innovative global programs are expected to file IND by the end of 2022, including HBM1020, HBM1022, and HBM1007."

IND • Oncology

Harbour BioMed Reports 2021 Interim Results (BioSpace) - “HBM1022 is a CCR8 antibody developed by HBM, which cross-reacts with the CCR8 target of cynomolgus monkeys, and has demonstrated its significant tumor growth inhibitory effect in mouse tumor models. As an innovative target, CCR8-targeted drugs have not yet entered the clinical development stage globally. It is expected that an IND application will be submitted in 2022.”

IND • Oncology